The Wall Street Journal examines how “Greece has seen decades of advances in public health rolled back, as a flood of illegal immigrants, a dysfunctional government and budget cuts ravage a once proud health-care system.” Noting “[o]ver the past two years, more than 50 endemic cases of [malaria] and more than 100 imported cases have been identified in Greece,” the newspaper writes, “The return of malaria, a scourge in developing countries, to Greece is a disturbing indicator of the nation’s decline since it crashed in 2009 under the weight of a debt binge.” The Wall Street Journal examines the history of malaria’s return to the country and how the government is responding. “In addition to malaria, public health officials say they are worried about rises in everything from infectious respiratory-tract diseases and skin conditions to tuberculosis and HIV,” the newspaper notes (Granitsas, 11/14).
The U.S. government, and in particular U.S. Global AIDS Coordinator Ambassador Eric Goosby, the head of PEPFAR, “have a unique opportunity to make [the program’s] money stretch farther and do more good, at very little cost to U.S. taxpayers: release the reams of data that PEPFAR and its contractors have already collected, at substantial cost — perhaps as much as $500 million each year,” Mead Over, a senior fellow at the Center for Global Development (CGD), writes in the Center’s “Global Health Policy” blog. “This would be a first step in what I hope will be [a] 2013 drive to improve the efficiency, the quality and the accountability of the U.S.’s most frequently praised foreign assistance program,” he states. Over goes on to describe the Data Working Group and its recommendations to PEPFAR (11/13).
Mary Beth Hastings, vice president of the Center for Health and Gender Equality (CHANGE), writes in the Huffington Post’s “Impact” blog that despite “the pervasive myth that no one wants female condoms,” “[d]emand is increasing because female condoms provide men and women with something they want: more options when it comes to protecting themselves.” USAID officials “were surprised to hear evidence of an unmet demand for female condoms,” Hastings says, adding, “[W]hen presented with evidence to the contrary, USAID started talking with different institutions about meeting the demand.” She continues, “To its credit, the U.S. government is a global leader on female condoms. But there is still room for improvement.”
“Private philanthropists in the European Union and the U.S. spent some $644 million on global HIV/AIDS programs in 2011, a five percent increase from 2010, largely driven by funding from a small number of large donors, a new report [.pdf] has revealed,” IRIN reports. “In their annual report, two groups — the U.S.-based Funders Concerned About AIDS (FCAA) and the European HIV/AIDS Funders Group (EFG) — reported that U.S. funders spent $491 million in 2011 while E.U. funders spent $170 million,” the news service writes (11/9). The report notes in a footnote that “$17.4 million was deducted from the combined total to avoid double-counting of grants that were given between U.S. and European-based funders and re-granted in 2011” (November 2012).
Recent successes in increasing the treatment and decreasing the incidence of HIV/AIDS, tuberculosis (TB), and malaria, along with other global health advances, “is thanks to the hard work and cooperation of people from many different walks of life: politicians of all stripes, business leaders, grassroots activists, clergy, health workers, government agencies and many more,” Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, writes in the Huffington Post “Impact” blog. She says the Global Fund to Fight AIDS, Tuberculosis and Malaria has been “[c]entral” to these developments, and the “U.S. government has been a crucial leader in supporting international health and the Global Fund.” She adds, “Sustained commitment will ensure more lifesaving success.” Derrick also recognizes the work of doctors and businesses.
The BMJ examines the history of fraud allegations against the Global Fund to Fight AIDS, Tuberculosis and Malaria and the organization’s ongoing reform efforts. “Most observers agree that after a honeymoon first decade, the Global Fund had grown so big, and the economic climate and attitudes to diseases such as AIDS have changed so dramatically, that more rigor and efficiency was needed, fraud or no fraud,” BMJ writes. The Fund is expected to appoint a new director “and a new funding model, to be announced on November 15, [which] are supposed to get things back on track” (Arie, 11/12).
“Look in the global strategies for HIV, [tuberculosis (TB)], malaria, maternal and child health, polio eradication, [neglected tropical diseases (NTDs)], and [non-communicable disease (NCDs)] — among many others — and you’ll see Nigeria at or near the top of the ‘Must Win’ countries,” Todd Summers, a senior adviser at the Center for Strategic & International Studies’ (CSIS) Global Health Policy Center, writes in the CSIS “Smart Global Health” blog. “Home to 170 million people, many of them desperately poor, Nigeria carries a huge and disproportionate share of burden for many of the world’s most deadly diseases,” he writes, noting the country, “one of the most important countries for all three diseases, is losing more in revenues than all of the Global Fund’s annual contributions combined.” He continues, “So, somehow, the Nigerian government needs to do a better job of capturing the revenues it’s due, and channeling a greater percentage of that revenue to the urgent health needs of its citizens, but that doesn’t seem to be happening.” However, Summers concludes “there’s some good news to report” on overall governance in the country, and he provides some examples (11/8).
“With donor money to fight HIV and AIDS falling, spending in sub-Saharan Africa must be targeted to get the best results,” Bjorn Lomborg, director of the Copenhagen Consensus Center, writes in the Guardian’s “Poverty Matters” blog, noting, “Sub-Saharan Africa has 10 percent of the world’s population but is home to 70 percent of those living with HIV and AIDS.” He continues, “The problem is neither beaten nor going away: new infections continue to outpace the number of people put on treatment,” and writes, “One of the biggest impediments to the fight is the incorrect perception in developed nations that the epidemic is beaten. Thanks to donor fatigue and tougher economic conditions, many donor countries have reduced their contributions significantly.”
“As the northern Indian state of Rajasthan rolls out an ambitious universal health care plan, the discontent of the state’s doctors stands in stark contrast to the joys of the 68 million people who will benefit from the scheme,” Inter Press Service reports. “Just a little over a year ago, the state government began supplying free generic drugs to its massive population, effectively stripping doctors of the ability to prescribe more expensive branded medicine,” IPS writes. The news service notes, “Some 350 essential generic drugs are now being distributed free of cost,” and, “[a]ccording to news reports, over 200,000 people are currently taking advantage of the program.”
Writing in USAID’s “IMPACTblog,” Dereje Bisrat, monitoring and evaluation adviser for the Supply Chain Management System (SCMS), discusses the PEPFAR-funded program, which is administered by USAID and “works with Ethiopia’s Pharmaceutical Fund and Supply Agency (PFSA), nine regional health bureaus, and more than 1,717 health facilities to improve access to HIV/AIDS treatment” in the country. She tells the story of Neima Mohammed, an Ethiopian refugee who, after living in Djibouti for 10 years, returned to her home country to seek treatment through the program, writing, “This story might have ended with Neima’s fateful decline in health. Fortunately, thanks to friends back home, Neima learned Ethiopia was embarking on efforts to provide free antiretroviral treatment to thousands of people living with the disease” (11/6).